Found 383 Results - Page 36 of 39
T-PLL
TCL1 for inversion 14 and t(14;14); TRA for t(X;14)
TdT
Anti-TdT antibody labels normal cortical thymocytes and primitive lymphocytes. Anti-TdT antibody detects an enzyme found in the nucleus of normal hematopoietic cells, normal cortical thymocytes and in the cytoplasm of megakaryocytes of the bone marrow. TdT expression is seen in over 90% of acute lymphoblastic lymphoma/ leukemia cases with the exception of pre-B-Cell ALL. TdT expression is not seen in normal mature T-or B-lymphocytes. Anti-TdT is positive for approximately one third of all cases of chronic myeloid leukemia, making it a good indicator of better response to chemotherapy.
TFE3
This antibody is directed against a cytoplasmic epitope of the trefoil factor family 3 (TFF3) protein present in epithelial cells. This antibody may be used to aid in the identification of intestinal metaplasia (IM) of the esophagus.
Thrombomodulin
Thrombomodulin is a transmembrane glycoprotein composed of 575 amino acids (molecular weight 75 kD) with natural anticoagulant properties. It is normally expressed by a restricted number of cells, such as endothelial and mesothelial cells. In addition, synovial lining and syncytiotrophoblasts of human placenta also express thrombomodulin.1-3 Anti-thrombomodulin has demonstrated positivity in benign vascular tumors such as hemangioma and most malignant vascular tumors (Kaposi’s sarcoma and epitheliod hemangioendothelioma).1-2 Hence, anti-thrombomodulin serves as a sensitive marker for lymphatic endothelial cells and their tumors.1-2 There has also been recent interest in the use of anti-thrombomodulin as an immunohiostochemical marker for mesothelial cells and malignant mesotheliomas.3-8 Anti-thrombomodulin is immunoexpressed in a variety of other tumors including urothelial cell carcinomas.9,10
Thyroglobulin
Anti-Thyroglobulin antibody reacts with human thyroglobulin as demonstrated by a single band of immunoblotting in a lysate of human thyroid tissue. The vast majority of follicular carcinomas of the thyroid will give positive immunoreactivity for thyroglobulin even though sometimes only focal. Poorly differentiated carcinomas of the thyroid are frequently thyroglobulin negative. Adenocarcinomas of other than thyroid origin do not react with this antibody.
TIA
TIA1 (T-cell intracytoplasmic antigen) monoclonal antibody reacts with a 15 kDa cytoplasmic granule-associated protein, expressed in lymphocytes processing cytolytic potential. Most anaplastic large cell lymphomas react with TIA1. TIA1 also reacts with most large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, subcutaneous T-cell lymphomas and pulmonary angiocentric lymphomas of T or NK phenotype. All B-cell lymphomas, Hodgkin and lymphoblastic leukemias are negative for TIA1.
TP53 Mutation Analysis
TP53 encodes a tumor suppressor protein that normally responds to diverse cellular stresses to induce cell cycle arrest, apoptosis, senescence, DNA repair or changes in metabolism. Somatic, loss of function mutations in TP53 are one of the most frequent in cancer and result in loss of the anti-proliferative and tumor-suppressive effects of the p53 protein. In some malignancies, such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), TP53 mutations are associated with an adverse prognosis resulting in the use of more aggressive treatment. Somatic mutations can also be associated with age-related clonal hematopoiesis in the absence of overt hematologic malignancy. Germline TP53 mutations are associated with Li-Fraumeni Syndrome – a familial predisposition to a variety of malignancies including sarcomas, breast carcinoma, gliomas and adrenocortical carcinomas. This DNA test is performed by targeted next-generation sequencing (NGS) and will detect mutations within the sequenced regions of TP53 exons 2 - 11 (NM_000546.5). See the table below for the specific regions sequenced by this assay. The reference genome assembly used for alignment and variant calling is hg19 (GRCh37).